Vivoryon Therapeutics NV (FRA:05Y) Net Change in Cash : €-7.99 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Vivoryon Therapeutics NV Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Vivoryon Therapeutics NV's Net Change in Cash for the six months ended in Dec. 2023 was €-11.02 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.99 Mil.

Vivoryon Therapeutics NV Net Change in Cash Historical Data

The historical data trend for Vivoryon Therapeutics NV's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivoryon Therapeutics NV Net Change in Cash Chart

Vivoryon Therapeutics NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

37.74

-15.22

-11.65

11.89

-7.99

Vivoryon Therapeutics NV Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															-5.17	9.72	2.17	3.03	-11.02

Vivoryon Therapeutics NV Net Change in Cash Calculation

Vivoryon Therapeutics NV's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-21.541	+	-10.514	+	24.157	+	-0.095
	=	-7.99

Vivoryon Therapeutics NV's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -1.258 + -10.505 + 0.757 + -0.013

= -11.02

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-7.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Vivoryon Therapeutics NV's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivoryon Therapeutics NV (FRA:05Y) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivoryon Therapeutics NV (FRA:05Y) » Definitions » Net Change in Cash

Comparable Companies

XAMS:BAI XAMS:PHARM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN XBRU:UCB RPRX

Traded in Other Exchanges

VVY:Netherlands

Address

Weinbergweg 22, Halle, SN, DEU, 06120

Website

https://www.vivoryon.com

Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and PQ1565. Geographically, the majority is from Greater China.

Vivoryon Therapeutics NV (FRA:05Y) Headlines

No Headlines